About James Breitmeyer
James Breitmeyer is CEO and director at Altay Therapeutics.
Experience
This experience comes from James Breitmeyer's profile and from SEC filings. For roles taken from filings, the years are when the filings name James Breitmeyer in the role, so the role may have started earlier or lasted longer.
Altay Therapeutics, Inc. Current
Chief Executive Officer, Board Director
2026 – Present · San Carlos, CA
Develops experimental drugs for people with muscular dystrophy, inflammatory diseases and cancer.
VI
Vaxart, Inc. Current
Board Member
2026 – Present
SF
SOLVE FSHD Current
Operating Partner
2025 – Present
OT
Oncternal Therapeutics
President & CEO, Board Director
2015 – 2025
OI
Otonomy, Inc
Member Board Of Directors
2018 – 2022
ZO
Zogenix
Board Director
2012 – 2022
BN
Bavarian Nordic
President ImmunoOncology, Corporate Executive Vice President
2013 – 2014
CP
Cadence Pharmaceuticals
Executive VP Development & Chief Medical Officer
2006 – 2012
EC
Eli Lilly and Company
Vice President
2001 – 2006
II
ImmunoGen, Inc.
Scientific Advisor
1989 – 1991
Key Colleagues at Startups
The people James Breitmeyer works with at each company, as listed on that company's latest Form D.
Altay Therapeutics, Inc. · Form D, Oct 2, 2026
AO
Ali Ozes
Founder and CSO
EB
Eric Bjerkholt
Director
MG
Mike Grey
Executive Chair
Ester Sklarsky
Board Director
AK
Aidan King
Director
CJ
Chelsea Johnson
Director